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Purpose. There is evidence that cholesterol affects the ATPase and transport functions of P-glycoprotein
(P-gp). To study the influence of cholesterol on P-gp in a well defined lipid environment, we
reconstituted P-gp in egg phosphatidylcholine (PhC) and PhC/cholesterol proteoliposomes with
negligible residual amounts of detergents.
Materials and methods. P-gp proteoliposomes were prepared by continuous dialysis from micelles
consisting of P-gp, lipids, sodium dodecyl sulfate and cholate. Basal and modulator-induced ATPase
activities were studied in an established enzyme assay. Modulator affinities to P-gp and to the lipid
bilayers were determined by equilibrium dialysis.
Results. In the absence of cholesterol the basal ATPase activity was six fold lower than in the presence
of 20 or 40% cholesterol, and no P-gp binding and ATPase induction was detected for the tested
modulators verapamil and progesterone. In proteoliposomes containing 20 and 40% cholesterol,
respectively, the modulators showed significant P-gp binding and ATPase activation. The concentration
of the modulators for half maximal activation of the ATPase was higher with 40% than with 20%
cholesterol.
Conclusions. Cholesterol influences P-gp in three ways: (a) it enhances its basal ATPase activity, (b) it
renders P-gp sensitive towards the modulators verapamil and progesterone and (c) it affects the
modulator concentration at half maximal ATPase activation.
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INTRODUCTION
The multi-drug resistance protein P-glycoprotein (P-gp) is
an efflux transporter for a wide variety of drug compounds and
cytotoxins. The 170 kDa ATP binding cassette (ABC) protein
contains 12 transmembrane domains and two cytosolic ATP-
binding sites. It is encoded by the MDR1 (ABCB1) gene and
is expressed under physiological conditions in tissues with
excretory functions, such as the small intestine, liver and
kidney, and at blood-tissue barriers such as the blood-brain
barrier, blood-testis barrier and blood-placenta barrier. It is
typically but not exclusively localized in the apical plasma
membrane domain of P-gp expressing cells (1). P-gp gets
frequently upregulated in tumor cells upon treatment with
cytotoxic drugs, causing multi-drug resistance by expelling a
wide palette of chemotherapeutics from these cells. For
reviews see (1–3).
The transported substrates have no common structural
features which would point to a well defined binding pocket
in the transporter and which would allow to clearly distin-
guish them from non-substrates. As P-gp substrates are
relatively lipophilic, it is assumed that the binding to the
transporter occurs from within the lipid bilayer (2). Several
studies on drug–P-gp interactions give indeed evidence for
drug binding sites within the transmembrane domains of the
protein (2,4–6). This is in line with the observations that the
transport and ATPase activities of P-gp are strongly depen-
dent on the lipid environment (7). P-gp may contain various
binding sites for different compounds or display one common
binding pocket of high flexibility to enable an induced fit
mechanism (8). In addition to the model of direct drug
binding to the transporter, indirect drug/P-gp interactions via
the lipid bilayer or a pH gradient were discussed (9).
P-gp hydrolyses ATP in the absence of known substrates
when reconstituted in a lipid bilayer environment; this is
defined as the basal ATPase activity. The ATPase activity is
significantly enhanced in the presence of many transported
substrates and of so called modulators. The latter activate the
P-gp ATPase activity without undergoing a significant P-gp
related net transport. This phenomenon may occur for
compounds which are translocated by P-gp but have a high
1993 0724-8741/07/1100-1993/0 # 2007 Springer Science + Business Media, LLC
Pharmaceutical Research, Vol. 24, No. 11, November 2007 (# 2007)
DOI: 10.1007/s11095-007-9326-0
1 Department of Chemistry and Applied Biosciences, Institute of
Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Strasse 10,
8093, Zurich, Switzerland.
2 To whom correspondence should be addressed. (e-mail: skraemer@
pharma.ethz.ch)
ABBREVIATIONS: CHAPS, 3- [ (3 -cho lamidopropyl ) -
dimethylammonio]propanesulfonate; DTT, Dithiothreitol; DMPC,
Di-myristoyl phosphatidylchol ine; DPPC, Di-palmitoyl
phosphatidylcholine; PBS, Phosphate buffered saline; TNE, Tris/
NaCl/EDTA buffer; P-gp, P-glycoprotein; PhC, Phosphatidylcholine;
SDS, Sodium dodecyl sulfate; SUBS, Standardized universal buffer
solution.
passive permeation rate across the membrane, exceeding the
transport efficiency of the protein (10).
P-gp is enriched in detergent-insoluble membrane
domains, the so called rafts, which contain relatively high
amounts of cholesterol and sphingolipids (11–13). Cholester-
ol plays a crucial role for the function of P-gp as an ATPase
and a transport system. In cell culture, the sterol controls P-gp
functions and P-gp localization (11–18). In general, the
ATPase activity of P-gp decreased upon depletion of cells
from cholesterol and increased upon repletion or saturation
of the cells with cholesterol.
It is still not known how the sterol influences the P-gp
ATPase and transport functions (1). Cholesterol may be a
substrate of P-gp transport and therefore increase the
ATPase activity in a similar manner as many known P-gp
substrates. This is supported by several studies (19). Howev-
er, the direction of the transport is not clear. Transport has
been described as cell influx or translocation from the
exoplasmic to the cytoplasmic membrane leaflet (20), as well
as from the cytoplasmic to the exoplasmic leaflet (18).
Alternatively, cholesterol could directly interact with P-gp,
enhancing its ATPase activity, without being transported. A
third possibility is given by the influence of cholesterol on the
characteristics of a lipid bilayer (15, 21). The sterol could thus
indirectly affect the function and activity of P-gp via the
membrane properties.
That cholesterol affects the ATPase activity of P-gp has
not only been shown with P-gp expressing cells but also with
proteoliposomes, i.e., after P-gp reconstitution in the lipid
bilayer of lipid vesicles. Proteoliposomes have the advantage
over whole cells that the transporter can be studied as an
isolated protein. Indirect effects by a cellular response can be
excluded. A great part of our current knowledge about the
influence of the lipid environment on the efflux transporter
P-gp comes from excellent work with P-gp proteoliposomes
(7,14,22–30).
The work with reconstituted P-gp is hampered by the
fact that most systems contain considerable amounts of
residual detergents. The latter generally affect the activity
of the transporter (31). In addition, mild detergents such as
CHAPS do not completely delipidate the protein upon
solubilization. The remaining lipids (about 50 phospholipid
molecules per P-gp molecule) could affect the activity and
function of the reconstituted transporter (32). We therefore
established a method to prepare P-gp proteoliposomes with
negligible amounts of residual detergents and lipids from the
source membrane. This was achieved by the use of the strong
detergents sodium dodecyl sulfate (SDS) and cholate for the
solubilization and reconstitution of P-gp into egg phosphati-
dylcholine (PhC) and PhC/cholesterol proteoliposomes. Both
detergents are quantitatively removable by dialysis due to
their relatively high critical micelle concentration. The
protocol was used to study the influence of cholesterol on
the basal and modulator-induced ATPase activity of P-gp
and on the binding of the modulators to the transporter. The
investigated modulators were verapamil and progesterone.
The basal P-gp ATPase activity was about six times
lower in the absence of cholesterol than in the presence of 20
or 40% (mol/mol total lipid) of the sterol. This low activity
remained unchanged upon addition of the studied modula-
tors and no specific P-gp binding of the tested compounds
was observed. In proteoliposomes containing 20 and 40%
cholesterol, respectively, the sterol not only enhanced the
basal ATPase activity in the absence of the tested modu-
lators, but also enabled P-gp binding and further ATPase
activation by the modulators. Finally, the modulator concen-
trations at half maximal ATPase activation were higher at
40% than at 20% cholesterol. Based on these findings we put




[N-methyl-3H]-verapamil (3.145 TBq/mmol, # NET-810),
[1,2,6,7-3H(N)]-progesterone (3.77 TBq/mmol, # NET 381)
and [2,4-3H]-cholic acid (560 GBq/mmol, # CUS55054000MC)
were purchased from Perkin Elmer Life Sciences (NEN,
Boston MA, USA) and sodium dodecyl-1-14C-sulfate (2.035
GBq/mmol, # L-2656) from Sigma (St. Louis MO, USA).
Adenosine triphosphate, di-sodium (ATP) #A2383,
orthovanadate, sodium #S6508, progesterone #P0130, and
(T)-verapamil #V4629 were supplied by Sigma (Buchs,
Switzerland), dithiothreitol (DTT) #43815, NADH #43420,
phosphoenolpyruvate #79418, pyruvate kinase #83330, sodium
dodecylsulfate (SDS) and 3-[(3-cholamidopropyl)-
dimethylammonio]propanesulfonate (CHAPS) were from
Fluka (Buchs, Switzerland). Lactate dehydrogenase #127876,
DNAse I and the protease inhibitor cocktail Complete\ were
supplied by Roche Diagnostics (Basel, Switzerland). All other
chemicals were of analytical grade.
Cell Cultures and Antibodies
P388/ADR cells were obtained from the National
Cancer Institute (Frederick, MD, USA). Cells were grown
in suspension in RPMI1640 medium (Invitrogen Corp., Basel,
Switzerland) containing 10% heat inactivated fetal bovine
serum and split 1:10 every 3–4 days. The monoclonal mouse
antihuman P-gp antibody C219 was supplied by DAKO
Corp. (DakaCytomation, Carpinteria, CA, USA).
Purification of P-glycoprotein
About fourI108 P388/ADR cells suspended in 2 ml PBS,
pH 7.0 (50 mM Na2HPO4/NaH2PO4, 130 mM NaCl)
containing 10 mM MgCl2, 1 mM dithiothreitol (DTT), 0.4
mg/ml DNAse I and protease inhibitor cocktail Complete\
were homogenized with 50 strokes of a Dounce homogenizer
at 1,000 rpm. The membrane fragments were collected by
centrifugation at 200,000 g for 1 h at 4-C. The pellet
containing the membrane fragments was solubilized in 2 ml
50 mM Na2HPO4/NaH2PO4, pH 7.4, containing 1 mM DTT
in 2% (m/v) SDS. After solubilisation the preparation was
diluted with 50 mM Na2HPO4/NaH2PO4, pH 7.0, containing
1 mM DTT to 1% SDS. P-gp was purified from the
solubilized membrane fragments by HPLC according to
(33) with some modifications. Briefly, about 4 mg protein
were injected on a hydroxyapatite cartridge (Econo-Pac*
CHT-II Biorad, Hercules CA, USA) and eluted with a
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sodium phosphate gradient (50 to 650 mM phosphate), pH
7.0, containing 0.5% SDS and 1 mM DTT. The buffer
components were incubated at 40-C and the cartridge was
heated to 30-C to prevent SDS precipitation. P-gp eluted at
about 530 mM phosphate and was concentrated with
Vivaspin 15R Hydrosart\ concentrators (mw cutoff 100,000,
Sartorius, Germany) before being stored at j80-C. The
concentrates contained 3–5 mg protein per 108 cells starting
material. This purification protocol results in P-gp which is
virtually free of lipids (33).
Reconstitution of P-glycoprotein
Protein-free liposomes of the final lipid composition
were prepared by extrusion in PBS, pH 7.4 (34). The
liposomes were subsequently dissolved by 30 min incubation
with sodium cholate at 60-C at a lipid/detergent molar ratio
between 0.5 (PhC/cholesterol liposomes) and 0.72 (PhC
liposomes) to form micelles. Complete solubilization was
confirmed by dynamic light scattering with a Zetasizer 3000
HSA (Malvern Instruments, Malvern, UK).
Purified P-gp (between 1.5 and 5 mg) in phosphate
buffer containing õ0.25% SDS (see above) was added to the
micelles (between 15 and 50 mg lipids) at room temperature
in a total volume between 6 and 10 ml. All subsequent steps
were performed at room temperature to prevent SDS
precipitation. After equilibration over night under argon
the protein/lipid micelles were continuously dialysed against
20 l of PBS containing 1 mM DTT and Complete\, pH 7.4,
by means of a Liposomat (Diachema, Munich, Germany)
equipped with a high permeability preconditioned cellulose
membrane with an mw cutoff of 10,000 and a size of 18 18 cm2
(Diachema). Flow rates were 0.6 ml/min on the micelle side
and 2.5 ml/min on the buffer side (35). Dialysis membranes
were exchanged 2–3 times during the dialysis.
To monitor detergent removal, 3H-cholate and 14C-SDS
(20,000 Bq/ml each) were added to the micelles together with
the purified P-gp. Samples were taken during the dialysis to
confirm the stability of the protein by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and immunoblotting as
well as to determine the ATPase activity and the detergent
concentration. After 96 h of continuous dialysis the
proteoliposomes were immediately used for the ATPase
assays. The protein content of the final proteoliposomes was
determined with the DC protein assay kit from Biorad with
bovine serum albumin as standard. PhC and cholesterol
concentrations were determined by HPLC as described (36).
Density Centrifugation and SDS-PAGE
Proteoliposomes (2 ml) were transferred to an equal
volume of 80% (w/v) sucrose in TNE (25 mM Tris, 150 mM
NaCl, 5 mM EDTA, and Complete\, pH 7.4) into a
centrifuge tube and overlaid with 2 ml each of 30%, 20%,
10% and 1.5 ml of 5% sucrose in TNE. After centrifugation
at 200,000 g for 19 h at 4-C, proteoliposomes were visible
as a turbid band in the upper part of the tube corresponding
to a density range between 1.03 and 1.05 g/cm3 as determined
from the refractive indices. Fractions of 1 ml were collected
and the P-gp distribution was studied by SDS-PAGE, 7.5%,
and immunoblotting with the anti-P-gp-antibody C219.
ATPase Kinetic Assay
The ATPase activities (Vapp) of the proteoliposomes
were determined at 37-C, pH 7.4, in 96 well plates (Corning,
flat bottom, black, #3915, Corning, Acton, MA, USA) with a
Synergy HT plate reader (BioTek, Winooski VT, USA) as
described (12). In brief, the ATP consumption was quantified
via an enzyme cascade resulting in NADH oxidation and
ATP recycling. The concentration of ATP was 9 mM (12).
The concentration-time profile of NADH was determined from
its fluorescence every 75 s. The protein content per well was
between 1 and 6 mg, the total sample volume per well 200 ml.
The Vapp/concentration profiles obtained with verapamil
and progesterone were fitted with Eq. 1, excluding the
modulator concentrations Q100 mM, at which an unspecific
inhibition occurred (12).




In Eq. 1, V0 denotes the difference between the activity
at a modulator concentration xYV (neglecting the inhibitory
effect at high concentrations) and the basal activity (Vbasal) in
the absence of modulator. K is the concentration of
modulator at half V0. For clarity, the data are shown in plots
with a logarithmic concentration scale. Data were fitted using
the Microsoft Excel Solver tool.
To test the influence of CHAPS, proteoliposomes were
incubated for 24 h with 400 mM of the detergent at 37-C
before they were diluted as stated above to determine the
ATPase activity at different verapamil concentrations. The
final CHAPS concentration in the assay was 28 mM.
Binding Affinity to P-glycoprotein
The binding of verapamil and progesterone to P-gp
proteoliposomes was determined at 37-C by equilibrium
dialysis with 0.2 ml dialysis cells and cellulose membranes
(mw cutoff 10,000, Dianorm, Munich, Germany). Total drug
concentrations were between 10j9 and 10j4 M, containing
1,600 Bq/ml 3H-verapamil and 2,700 Bq 3H-progesterone,
respectively. The protein concentration was between 0.1 and
0.5 mg/ml. Dialysis was performed in PBS, pH 7.4, containing
200 mM sodium vanadate, 10 mM MgCl2 and 1.2 mM ATP
(37). The dialyzed samples contained in addition õ0.5%
ethanol originating from the stock solutions of the modulators.
The dialysis was terminated after 5 h (38) and verapamil
and progesterone, respectively, were quantified in both cell
chambers by liquid scintillation counting. The protein and
lipid concentrations in the respective chambers were deter-
mined as described above.
The binding data were transformed to Scatchard plots
and the data obtained with the PhC/cholesterol proteolipo-
somes were further analyzed by non-linear curve fitting
according to Eq. 2
r
Cu
¼ n1  Ka1
1þKa1  Cu þ
n2  Ka2
1þKa2  Cu ð2Þ
where r is the ratio of bound compound [M] and total protein
[M] (mw 170,000, assuming 100% P-gp), Cu is the unbound
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drug concentration [M], ni is the maximal number of
compound molecules bound to the binding site(s) of class i
[-] and Kai [M
j1] is the association constant between a drug
molecule and a binding site of class i.
Membrane Affinity
The affinity of 3H-verapamil and 3H-progesterone to
liposomal membranes was determined by equilibrium dialysis
at 37-C (38). The pH was adjusted with a standardized
universal buffer solution (SUBS, (38)) as indicated. The drug
concentrations were 10j7 M and PhC concentrations were
about 1 mg/ml. Distribution coefficients (D) were calculated
according to Eq. 3 (34)
D ¼ CLB  CBð Þ  vLB= CB  vLð Þ þ 1 ð3Þ
where CLB is the molar solute concentration in the liposome-
containing chamber and CB in the buffer chamber. The
symbol vLB denotes the sample volume of the liposome
suspension, vL the volume of the lipophilic phase, i.e., the
lipid bilayers. This volume was calculated from the PhC
concentrations in the dialysis cells, which were determined by
HPLC (see above), and a density of 1.0 g/ml for the lipids.
The pH-dependent distribution of 3H-verapamil between the
lipid bilayer and the aqueous phase was fitted according to
Eq. 4 (34):
D ¼ aN  PN þ aI  PI ð4Þ
where aN and aI are the molar fractions of neutral and
ionized verapamil, respectively (pKa 8.9), and P
N and PI are
the partition coefficients of the two ionization species.
RESULTS
Characterization of P-gp Proteoliposomes
P-gp was purified from P388/ADR cells and reconstituted
into PhC, PhC/cholesterol 80/20 (mol/mol) and PhC/choles-
terol 60/40 liposomes, respectively, as described under Mate-
rials and Methods. The final protein concentration of a typical
preparation was 0.2 mg/ml. The protein to lipid ratio (w/w)
after reconstitution was between 0.10 and 0.13, corresponding
to molar ratios between 4.5 10j4 and 5.9 10j4.
As detergents can significantly affect the ATPase
activity of P-gp (31,39), the detergent concentrations in the
proteoliposomes were determined with radio-labeled SDS
and cholate (see Materials and Methods). The residual
concentrations were below the detection limit. The
corresponding lipid/detergent and protein/detergent ratios
are depicted in Table I. The respective detergent concen-
trations had no influence on the ATPase activity of rafts from
P388/ADR cells (12), which display high P-gp ATPase
activity (data not shown).
To test whether P-gp was stable during the 96 h of
dialysis needed to reach the low detergent concentrations,
samples were analyzed by SDS-PAGE and immunoblotting
after 9, 24, 48 and 72 h and at the end of the dialysis, i.e., after
96 h. As shown in Fig. 1a, no decomposition products were
visible on the blot and the amount of P-gp was similar at all
tested time points. The ATPase activity after 19 and 48 h of
dialysis was 67 and 82%, respectively, of the final activity
reached after 96 h, indicating the gain in activity by the
removal of the detergents (data not shown). In addition to
the dialysate all eluted fractions from the hydroxyapatite
cartridge were checked for P-gp decomposition products by
SDS-PAGE and immunoblot. No such products were
detected in several purification runs (data not shown).
To confirm the successful reconstitution of P-gp, a
density gradient centrifugation of the proteolioposome
preparation was performed and the density fractions were
analyzed by SDS-PAGE and immunoblotting. As shown in
Fig. 1b there was complete reconstitution indicated by the
localization of P-gp in the lipid containing turbid low density
fractions (fractions 1–4, 1.03–1.05 g/cm3). No P-gp was
detected in the high density fractions (fractions 5–9) where
soluble or aggregated proteins would accumulate. This result
was independent of the lipid composition.
The final P-gp proteoliposomes displayed a basal ATPase
activity between 16.6 and 101.0 nmol per min per mg protein
depending on the lipid composition of the proteoliposomes
(see next section). To verify that the observed ATPase
activity originated from P-gp, ATPase activities were deter-
mined at different concentrations of the monoclonal P-gp
antibody C219, which binds to both nucleotide binding
regions of P-gp and has been shown to inhibit its ATPase
activity (40). C219 reduced the basal activity of the proteoli-
posomes to (15.0T 2.6)% at 5 mg antibody and 5 mg P-gp per
ml. This was independent of the lipid composition. When the
proteoliposomes were incubated with 400 mM sodium ortho-
vanadate, an unspecific ATPase inhibitor (12,41), the ATPase
activity was decreased to a similar residual activity of
(12.4 T 3.7)% in all proteoliposomes.
The average size and size distribution of the proteolipo-
somes were characterized by dynamic light scattering with a
Zetasizer 3000 HSA (Malvern Instruments, Malvern, UK). All
proteoliposome preparations showed an average mean hydro-
dynamic diameter between 130 and 150 nm and a polydispersity
index <0.4 corresponding to a size variance of <63% assuming a
monomodal distribution. No signs of aggregates were observed
in the correlogram.
Table I. Residual Detergent in P-gp Proteoliposomes
Detergent Concentration
Detergent/Protein Ratio Detergent/Lipid Ratio
[M] [mg/mg] [mol/mol]a [mg/mg] [mol/mol]a
SDS <1.7 10j6 <2 10j3 <1.4 <3 10j4 <7 10j4
Cholate <4.0 10j7 <8 10j4 <0.3 <9 10j5 <2 10j4
The protein concentration was 0.21 mg/ml, the lipid concentration 1.8 mg/ml.
a Calculated with a molecular weight of 170,000 for P-gp and 780 for egg PhC, respectively.
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Influence of Cholesterol on the Basal and Drug-induced
ATPase Activity of Reconstituted P-gp
Cholesterol significantly influenced the basal ATPase
activity of the proteoliposomes. In the absence of cholesterol
(PhC proteoliposomes) it was (16.6 T 2.1) nmolminj1mgj1
(n = 36) but reached (101.0 T 8.1) nmolminj1 mgj1
(n = 36) in proteoliposomes containing 20% cholesterol and
(86 T 20) nmolminj1mgj1 (n = 54) in proteoliposomes
containing 40% cholesterol, respectively (Fig. 2a).
Next, we investigated whether cholesterol had an effect
on the ATPase activity in the presence of P-gp modulators.
Verapamil and progesterone are known to enhance the
Fig. 1. Confirmation of P-gp reconstitution into proteoliposomes by
SDS-PAGE and immunoblotting with the P-gp antibody C219. a
Samples were taken at the indicated time points during the detergent
dialysis. Per slot, 0.08% of the total volume, corresponding to 3.7 mg
protein of the final preparation (96 h), was loaded. b The final
preparation (after 96 h of dialysis) was analyzed by sucrose density
centrifugation. Of each fraction (1 to 11, top to bottom) 20 ml were
loaded on the gel. Fractions 8 and 9 as well as 10 and 11 were pooled.
Fig. 2. Influence of cholesterol on the ATPase activity of reconsti-
tuted P-gp. The ATPase activities of the P-gp proteoliposomes were
determined in the absence (a) and the presence of the modulators
verapamil (b) and progesterone (c). (b, c) PhC proteoliposomes
(squares); PhC/cholesterol 80/20 (circles); PhC/cholesterol 60/40
(triangles). The activities shown in b and c were normalized to the
respective basal activities. The concentration-dependent profiles
obtained with the PhC/cholesterol proteoliposomes were fitted as
described in the text (solid lines), the fit parameters are shown in
Table II. The symbols are mean values of 6 or 9 activity/
concentration profiles out of 2 or 3 independent experiments. Error
bars indicate the standard deviations.
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ATPase activity of P-gp at concentrations <100 mM but have
an inhibitory effect at higher concentrations that can be
attributed to unspecific effects on the protein or the
membrane (12). The ATPase activities of the cholesterol-
free and cholesterol-containing proteoliposomes were de-
termined at verapamil and progesterone concentrations
between 50 nM and 400 mM (Fig. 2b, c). For PhC
proteoliposomes no activation was detected over the whole
concentration range while at concentrations >50 mM the
ATPase activity was inhibited by both compounds. In the
proteoliposomes containing 20 and 40% cholesterol, respec-
tively, verapamil and progesterone enhanced the ATPase
activity at concentrations <100 mM. The maximal activities at
50 mM modulator were about two-fold higher than the
respective basal activities. The activity was decreased at
concentrations >50 mM. To further analyze the drug induced
activity profiles, data were fitted with Eq. 1, excluding the
concentrations with the inhibitory effect from the fit. The fits
are shown in Fig. 2. The mean ratios of the fitted maximal to
basal activities (V0/Vbasal) and the mean modulator concen-
trations at half-maximal activation (K) were derived from the
fits of the single experiments and are summarized in Table II.
The values for K of verapamil and progesterone were
dependent on the cholesterol content of the proteoliposomes
while V0/Vbasal was hardly affected. Both drugs were more
potent (had lower K values) in inducing the P-gp ATPase
activity in proteoliposomes containing 20% cholesterol than
with 40% cholesterol. The fitted K of both compounds was
about 6 fold lower with 20% than with 40% cholesterol.
Influence of the Detergent CHAPS on the ATPase Activity
in Egg PhC Proteoliposomes
Several earlier studies with P-gp reconstituted in PhC
(7,22,29) found a drug-induced increase of the ATPase
activity in the absence of cholesterol. Our findings are in
contrast to these data as the ATPase activity was not affected
by the tested modulators in the absence of cholesterol. The
differences between our system and published proteolipo-
somes are the type and removal method of detergents and
the content of residual detergents. We therefore tested the
influence of CHAPS, a frequently used detergent for P-gp
purification and/or reconstitution, on the ATPase activity of
egg PhC proteoliposomes prepared by our procedure. The
final concentration of 28 mM CHAPS had no significant
influence on the basal ATPase activity, however, with
verapamil the typical bell-shaped activity/concentration pro-
file was observed (Fig. 3).
Influence of Cholesterol on the Binding of Verapamil
and Progesterone to Reconstituted P-gp
To investigate whether cholesterol has an effect on the
binding of the modulators to P-gp, we studied the affinity of
verapamil and progesterone to cholesterol-free and cholesterol-
containing P-gp proteoliposomes by means of equilibrium
dialysis at drug concentrations between 10j10 and 10j4 M as
described under BMaterials and Methods^ section. Figure 4
shows the Scatchard plots of both drugs in proteoliposomes
containing 20% cholesterol. The plots revealed two binding
classes, one with a high affinity but a low number of
interaction sites and a second one with a lower affinity but
a higher number of interaction sites. The results were similar
for proteoliposomes with 40% cholesterol. The high affinity
was assigned to the binding to P-gp and the low affinity
interaction to the partitioning into the lipid bilayer. The
binding data were fitted with Eq. 2. The respective fit
functions are shown in Fig. 4. The good agreement between
the experimental data and the fit function corroborates the
underlying model, i.e., the co-existence of a relatively strong
specific binding with a low number of binding sites and an
unspecific affinity with high capacity. The first is interpreted
as the binding to P-glycoprotein, the latter as the membrane
affinity. The differences between the fitted parameters of the
proteoliposomes with 20 and 40% cholesterol were within the
experimental error of the single experiments. As the purity of
the enriched P-gp protein fractions is not known, no absolute
binding constants were calculated.
In order to elucidate the reason for the lack of P-gp
activation in the cholesterol-free proteoliposomes, we also
studied the binding affinity of verapamil and progesterone to
P-gp reconstituted in PhC proteoliposomes. The Scatchard
plots shown in Fig. 5 revealed only unspecific binding for
both compounds within the tested concentration range (see
above). In contrast to the cholesterol-containing proteolipo-
somes, no increase in binding affinity was detected at the low
concentrations. The lack of a distinct slope in the Scatchard
plot results from a high number of association sites. The
observed affinity was therefore assigned to the partitioning of
the drugs into the lipid bilayer. The calculated value of r/cu
was in accordance with the partition coefficients revealed
with liposomes (see below). In conclusion, no binding of the
drugs to P-gp was detectable in the absence of cholesterol.
Influence of Cholesterol on the Lipid Bilayer Affinity
of Verapamil and Progesterone
P-gp is proposed to extract its substrates directly from
the inner leaflet of the membrane (2). As the composition of
the lipid bilayer has a major influence on the drug-membrane
affinity and on the local drug concentration and arrangement
inside the membrane, it could affect the drug–P-gp interac-
tions. The influence of cholesterol on the lipid bilayer affinity
of verapamil and progesterone was determined with PhC
liposomes containing 0, 20 and 40% cholesterol, respectively.
The membrane affinity of the compounds was measured by
means of equilibrium dialysis and verapamil data were fitted
using Equation 4. Figure 6 shows the influence of cholesterol
on the lipid bilayer partitioning (D) of verapamil (between
pH 5 and 12) and progesterone (between pH 2 and 12),
respectively, and on the fitted partition coefficients of the
neutral compounds (PN) and of protonated verapamil (PI).
The PN of progesterone was decreased 1.8 fold upon
incorporation of 20% cholesterol in PhC liposomes.
Increasing the cholesterol content to 40% led to a further
decrease of PN by a factor of 1.6. In the case of verapamil, the
presence of 20% cholesterol decreased the affinity of the
neutral species (PN) 1.2 fold, increasing the cholesterol to 40 %
led to a further decrease by a factor of 2.4. The affinity of the
protonated verapamil (PI) was decreased 1.8 fold by
incorporation of 20% cholesterol and 1.4 fold by increasing
the amount of cholesterol from 20 to 40%.
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DISCUSSION
The present study was conducted with P-gp proteolipo-
somes which contained negligible amounts of residual
detergents. As P-gp was solubilized and purified with SDS
according to Dong et al. (33) it can also be expected that no
residual lipids from the P-gp source were present. The
absence of significant amounts of detergents and source
lipids makes this system unique and allows to investigate the
influence of the lipid environment and of drug compounds on
P-gp functions under well defined conditions.
Residual detergents in P-gp proteoliposomes may signif-
icantly influence the ATPase activity of the transporter (31).
The detergent CHAPS is frequently used for the purification
and reconstitution of P-gp. Romsicki and Sharom (42)
studied the influence of additional CHAPS on the ATPase
activity of P-gp in di-myristoyl PhC (DMPC) proteolipo-
somes prepared from P-gp/lipid/CHAPS micelles. The resid-
ual detergent concentration was <0.02% of the starting
concentration, corresponding to a concentration of <40 mM.
The addition of more detergent (Q õ30 mM) led to a
significant increase in the ATPase activity. The authors
assigned this effect to the permeabilization of the vesicles.
However, these data could also disclose the influence of the
detergent on the ATPase activity of the protein. CHAPS
restores P-gp ATPase activity even in the absence of lipids
(31) and verapamil was able to increase the ATPase activity
of P-gp in 0.4 mM of the detergent (32).
In our egg PhC proteoliposomes the P-gp ATPase
activity was not inducible by verapamil and progesterone in
the absence of cholesterol. This is in contrast to the findings
of other studies with PhC proteoliposomes (7,22,29). How-
ever, the incubation with CHAPS restored the verapamil-
Fig. 4. Scatchard plots of verapamil and progesterone binding to P-gp
PhC/cholesterol 80/20 proteoliposomes. Verapamil (a) and progester-
one (b) were incubated at various concentrations between 10j10 and
10j4 M with proteoliposomes (protein concentration between 0.1 and
0.5 mg/ml). Binding was determined by equilibrium dialysis at 37-C.
Solid lines show the fit functions for two binding classes as described in
the text. Results are from one representative experiment each.
Proteoliposomes with 40% cholesterol revealed similar Scatchard
plots.
Fig. 3. Influence of CHAPS on the ATPase activity of P-gp in egg
PhC proteoliposomes at different verapamil concentrations. Circles,
after incubation of the proteoliposomes with CHAPS, the final
detergent concentration in the assay was 28 mM. Squares, influence of
verapamil in the absence of detergent. Shown are mean values T
standard deviations of 4 independent experiments each. The basal
activity after CHAPS incubation did not significantly differ from the
activity in the absence of CHAPS.




Verap Progest Verap Progest Verap Progest
PhC 16.6 T 2.1 – – – – – –
PhC:Chol 80:20 101.0 T 8.1 227.0 T 14.8 196.7 T 15.9 2.24 T 0.02 2.04 T 0.02 0.56 T 0.05 1.88 T 0.12
PhC:Chol 60:40 85.6 T 20.0 182.1 T 42.7 175.8 T 44.1 2.19 T 0.05 2.24 T 0.08 3.56 T 0.49 10.58 T 1.81
Vbasal and V
0 [nmolminj1 mgj1 ]; K [mM]
Verap, verapamil; Progest, progesterone
a Mean values T standard deviations (n Q 36); b means of fitted values T standard deviations from six or nine activity/concentration profiles out
of two or three independent experiments each.
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inducible ATPase activity in the absence of cholesterol in our
assay. This indicates that P-gp is potentially functional in egg
PhC proteoliposomes. It confirms that the non-inducibility by
verapamil and progesterone, respectively, is indeed due to
the absence of cholesterol or any other membrane constitu-
ent which induces functionality of the ATPase and not due to
irreversible inactivation during the purification and reconsti-
tution procedures. It further emphasizes the influence of
residual detergent on the ATPase activity of the transporter.
The overlapping effect of cholesterol and CHAPS on the
function of P-gp, as found in our study, is not surprising,
considering the similarity in their molecular structure.
We can not exclude that P-gp is partially denatured in
our system due to the contact with the relatively strong
detergents SDS and cholate. However, the increase in
ATPase activity during dialysis and the typical behavior of
the PhC/cholesterol proteoliposomes in terms of ATPase
activity and activation by the modulators, indicates that at
least a significant part of the transporter is correctly folded.
Investigations by Dong et al. (33) and by Naito and Tsuruo
(57) have shown before that P-gp which was solubilized with
SDS or cholate regains its function after the removal of the
detergents.
The tremendous increase in the basal ATPase activity
caused by cholesterol is in line with all discussed possible
functions of the sterol: (a) It could be transported by P-gp
and therefore increase its ATPase activity. (b) Cholesterol
could affect the conformation and/or conformational flexibil-
ity of P-gp, i.e., freedom to change conformation upon drug
or ATP binding, by a direct interaction and therefore enable
its functionality as an ATPase without being transported. (c)
Cholesterol could indirectly affect the conformation and
conformational flexibility of P-gp via its influence on the
membrane properties, and therefore induce its activity as an
ATPase.
The binding to P-gp and the enhancement of the P-gp
ATPase activity by the two modulators verapamil and
progesterone was only observed in the presence of choles-
terol in the bilayer. This indicates that cholesterol has a direct
or indirect effect on the protein conformation, enabling the
interaction with the modulators. This effect would be
independent of the recognition of cholesterol as a transport
substrate by P-gp but would correspond to the above
discussed possible functions (b) and (c), respectively, of
cholesterol.
Saeki et al. (29) found a similar influence of cholesterol
on azidopine binding to a reconstituted P-gp fusion protein.
Evidence that the membrane environment affects the effi-
ciency of allosteric conformational changes of the protein
was demonstrated by Modok et al. (22). Their data suggest
that a raft-like lipid composition enhances the drug trans-
porter activity of P-gp.
Direct binding of cholesterol to P-gp could lead to the
above discussed conformational change in the protein (b). A
direct interaction of cholesterol with the P-gp site of
daunorubicin binding was suggested by Wang et al. (19)
based on ATPase assays with membrane vesicles from P-gp
overexpressing cells. The authors found a mixed type (non-
competitive) inhibition of the daunorubicin-induced ATPase
activity by cholesterol.
Fig. 6. Influence of cholesterol on the lipid bilayer affinities of
verapamil and progesterone. The pH-dependent partitioning of
verapamil (a) and progesterone (b) was determined with PhC
(squares), PhC/cholesterol 80/20 (circles) and PhC/cholesterol 60/40
(triangles) liposomes. The solid lines show the fit functions as
described in the text for (a) and mean values for (b).
Fig. 5. Scatchard plots for the binding of verapamil and progesterone
to P-gp proteoliposomes in the absence of cholesterol. Verapamil
(closed circles) and progesterone (open circles) binding to P-gp PhC
proteoliposomes was determined as described in Fig. 4 and in the
text. Only unspecific binding, i.e., partitioning into the lipid bilayer,
was detected as seen from the concentration-independent r/cu values.
Data are from one representative experiment each.
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Further evidence of a direct interaction between choles-
terol and P-gp was described by Kimura et al. (14).
Cholesterol bound to P-gp in the absence of lipids. This
could, however, be different within the lipid bilayer, consid-
ering the high affinity of the sterol to phospholipids and the
interaction between P-gp and phospholipids. Both equilibria
are in competition with the binding between cholesterol and
P-gp. It is still open how cholesterol distributes between P-gp
and the lipid environment.
An indirect effect of cholesterol on the conformation of
P-gp (c) could arise from its influence on the bilayer rigidity
and structure (21) or on the membrane thickness. The
addition of cholesterol to egg PhC bilayers could lead to a
favorable hydrophobic matching of the bilayer and the
protein, enabling its optimal function as an ATPase. Inclu-
sion of cholesterol to egg PhC bilayers increases the
hydrophobic thickness of the membrane from 26 to 33 A˚
(43,44) which better matches the hydrophobic core of P-gp
that has been estimated to be 34 A˚ (45). A hydrophobic
mismatch could lead to a change in the transmembrane
orientation of the a-helices, distribution of conformational
states or conformational mobility of the transmembrane
domains (46). This could affect P-gp activity as the protein
undergoes large conformational rearrangements during its
transport cycle (47).
Further insight into the effect of cholesterol on P-gp
function is given by the comparison of the kinetics in the
presence of 20 and 40% cholesterol in the bilayers. In our
study, the modulator concentrations at half maximal induc-
tion of the ATPase activity (K) are dependent on the
membrane content of cholesterol. They are higher with
40% cholesterol than with 20%. The membrane affinities of
both modulators are higher with 20% cholesterol than with
40%. Assuming Michaelis-Menten conditions, K is related to
the binding affinity of the modulators to P-gp. In this case,
cholesterol would influence the binding of the modulators to
P-gp. Alternatively, the differences in K could reflect differ-
ences in processes such as the release of the modulator after
ATP hydrolysis or the interaction of the protein with ATP. In
addition, K could be affected by the membrane affinity, if
one (or both) of the partitioning rate constants is rate-
determining for the binding to the active protein or the
release from the binding site. However, increasing the
cholesterol content from 20 to 40% had a higher impact on
the concentrations K than on the membrane affinities D of
the two modulators. This makes it unlikely that the partition-
ing kinetics are rate-limiting for the P-gp binding kinetics.
We would also like to note here, that the membrane affinity
must not necessarily be positively related with the P-gp
binding affinity. An increase in membrane affinity caused by
the lipid composition is at the cost of both equilibria the drug
partitioning between the water phase and the membrane as
well as the drug partitioning between the protein and the
membrane. At equilibrium, the protein binding constant
(determined from the protein bound concentration and the
aqueous concentration) may be independent of the mem-
brane affinity.
The maximal ATPase activities (V0) induced by verap-
amil and progesterone in the presence of 20 and 40%
cholesterol, respectively, were all similar, indicating that the
P-gp function and therefore conformation is unchanged
comparing the two membrane environments. The fact that
the cholesterol content (Q20%) has an influence on K but has
no influence on the functionality of P-gp, indicates that
cholesterol—in addition to enhancing the basal ATPase
activity and rendering the protein sensitive towards the
modulators—may indeed interact with the binding sites of
the modulators in a competitive manner.
Kimura et al. (14) observed a similar influence of
cholesterol on K and V_ of verapamil with reconstituted P-gp.
Whether K was affected by cholesterol was dependent on the
molecular weight of the tested compounds in their study.
While cholesterol affected the K of verapamil (mw 455) it had
no effect on the K of paclitaxel (mw 854). Their model
suggests that cholesterol may fill up the binding site when
small compounds, such as verapamil bind to P-gp, but is
excluded from the binding site when larger compounds, such
as paclitaxel bind. In their system P-gp was activated by the
tested compounds in the absence of cholesterol while P-gp was
not activated under these conditions in our study. It will be
interesting to see whether paclitaxel and other larger com-
pounds can activate P-gp under our conditions in the absence
of cholesterol. This would support the model of Kimura et al.,
i.e., that cholesterol is only involved in the binding and
activation by small compounds, such as verapamil.
Comparing the concentrations of cholesterol and mod-
ulator within the bilayer at maximal ATPase activation in our
study, the model of competitive binding appears realistic.
The local modulator concentrations within the membrane at
maximal ATPase activation are about 50 mM as estimated
from the liposome partition coefficients D (õ103) and the
aqueous modulator concentrations (50 mM). The local
cholesterol concentration within the bilayer is in the range
of 260–500 mM (the total lipid concentration within the
bilayer is õ1.3 M). Depending on the protein binding affinity
of the modulator and of cholesterol, respectively, and on
their respective affinities to the membrane lipids—which may
compete with the protein binding—a significant competition
between cholesterol and the modulator for a P-gp binding
site is possible. This model of competitive binding is in
agreement with the increased K at the higher cholesterol/
lipid ratio.
Romsicki and Sharom (7) found a good correlation
between P-gp binding affinities and membrane affinities with
vinblastine, verapamil and daunorubicin in egg PhC, DMPC
and di-palmitoyl PhC (DPPC) membranes (note that these
proteoliposomes do not contain cholesterol but may contain
residual CHAPS). In the same work the membrane affinity
and P-gp binding affinity, respectively, of verapamil did not
appear to affect K in the respective proteoliposomes. In turn,
the ratio between the maximal inducible ATPase activity and
the basal activity (V0/Vbasal) was lipid-dependent. These
findings could point to an effect of the lipid environment on
the protein which is not directly related to the drug binding
site, i.e., an effect of incompetitive character. In their study,
the lipid environment could affect the P-gp function in
dependence of the lipid chain length and order, which
determine the thickness and rigidity of the bilayer.
In general, further effects of cholesterol may occur and
be relevant for P-gp function: cholesterol may be needed as a
substrate for counter transport when drug substrates or
modulators are moved from the cytoplasmic to the exoplas-
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mic membrane leaflet by P-gp. Cholesterol and the lipid
composition in general, could bring P-gp substrates or
modulators in a position within the bilayer which is favorable
for their recognition by P-gp. An inhomogeneous distribution
of the lipids within the bilayer, e.g., an increase of cholesterol
in the vicinity of P-gp, could affect the local distribution of
drug compound within the membrane. Finally, P-gp is
discussed as a phopholipid transporter (23,48) and could
therefore have an indirect effect on the distribution of
cholesterol between the two membrane leaflets.
Based on our results and on studies cited in this work,
one could speculate that cholesterol is transported by P-gp
and regulates the P-gp transport (and ATPase) function via
its content within the bilayer. In the absence of cholesterol,
P-gp displays low activity and only in the presence of
cholesterol, P-gp gets fully functional and regulates the
distribution of the sterol between the cytosolic and exosolic
membrane leaflets. In this conformation, P-gp is further
activated by the modulators verapamil and progesterone,
which compete with cholesterol for the binding to the
transporter. Further investigations have to show whether
other membrane constituents than cholesterol can activate P-gp
and whether other compounds than those we tested can interact
with P-gp in the absence of the sterol.
Considering the substantial influence of the membrane
environment on P-gp, findings with reconstituted P-gp have
to be interpreted in the light of all system components.
Detergents and additional adjuvants from the purification
and reconstitution procedures can affect the behavior of the
transporter, as we have shown for CHAPS. The most
frequently used detergents for the purification of P-gp beside
CHAPS (26,28,29,32,39,42) are n-octyl b-D-glucopyranoside
(octyl glucoside) (27,30,49–53) and n-dodecyl or n-decyl b-D-
maltoside (14,22,25,33,51,54–56). Octyl glucoside had activat-
ing as well as inhibiting effects on the ATPase activity of
CHAPS-solubilized P-gp, depending on the glucoside con-
centration (39). Alternatively, other detergents such as
cholates (57), lyso PhC (58) and some non-ionic detergents
(59) were investigated. The influence of most of these
detergents on membrane-reconstituted P-gp remains to be
investigated. Several systems contain protease inhibitors in
addition and preparations of histidine-tagged P-gp generally
contain considerable amounts of imidazole. These additional
compounds are potential substrates, modulators or inhibitors
of P-gp. Their assay concentrations are generally not known
and their influence on the P-gp behavior is rarely examined.
The lipid composition of the reconstituted system is
crucial for the behavior of the transporter. Depending on the
purification technique the protein is delipidated to different
degrees. Lipid compositions for reconstitution range from
single phospholipids of synthetic or natural origin to lipid
mixtures of phospholipids with or without cholesterol.
Beside reconstituted P-gp, membrane vesicles of P-gp-
expressing cells are used to investigate P-gp characteristics.
Depending on the cell type, the lipid composition can vary
strikingly. Membrane vesicles were prepared from mamma-
lian cells (60–64) and from P-gp-transfected insect cells
(65,66). In the light of our findings it is interesting to note
that plasma membranes from insect cells (Sf9) contain about
ten times less cholesterol than plasma membranes from
higher eukaryotic cells (67).
In conclusion, cholesterol exerts three effects on P-gp:
(a) it increases its basal ATPase activity, (b) it enables P-gp
binding and activation by the modulators verapamil and
progesterone and (c) it may compete with verapamil and
progesterone for the same binding site(s).
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